Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Clinical trial NCT04281498 · COMPLETED
Trial details
- NCT number
- NCT04281498
- Sponsor
- John Mascarenhas
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-14
- Primary completion
- 2023-05-30
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.